ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
The therapeutic potential of brazilin in bladder cancer: inhibition of DNA topoisomerase I and tumor growth suppression.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to investigate the therapeutic effects of brazilin in the treatment of bladder cancer through the inhibition of DNA topoisomerase I (Topo 1) and to explore its underlying mechanisms. In vitro experiments were conducted using bladder cancer T24 cell line and in vivo experiments were performed using a bladder cancer mouse model. The effects of brazilin on cell proliferation, apoptosis, and DNA damage were evaluated. RT-qPCR and Western Blot analyses were used to assess the expression of Topo 1 mRNA and protein after treatment with brazilin. Additionally, tumor growth inhibition and potential side effects were evaluated in the animal model. Brazilin significantly inhibited bladder cancer cell proliferation and induced apoptosis and DNA damage in vitro. The expression of Topo 1 was downregulated at both the mRNA and protein levels, suggesting that brazilin exerts its effects by inhibiting Topo 1 activity. In vivo, brazilin markedly suppressed tumor growth in the bladder cancer mouse model, with no significant toxic effects observed. Brazilin shows potential as a therapeutic agent for bladder cancer by inhibiting Topo 1 activity, leading to suppressed tumor growth and cellular damage. This study provides experimental evidence supporting the potential use of brazilin as a novel anticancer drug for bladder cancer treatment.
Indexed as
Identifiers
40223033What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.